Search Results - "De Jonge, Maja"

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial by Subbiah, Vivek, Kreitman, Robert J., Wainberg, Zev A., Gazzah, Anas, Lassen, Ulrik, Stein, Alexander, Wen, Patrick Y., Dietrich, Sascha, de Jonge, Maja J. A., Blay, Jean-Yves, Italiano, Antoine, Yonemori, Kan, Cho, Daniel C., de Vos, Filip Y. F. L., Moreau, Philippe, Fernandez, Elena Elez, Schellens, Jan H. M., Zielinski, Christoph C., Redhu, Suman, Boran, Aislyn, Passos, Vanessa Q., Ilankumaran, Palanichamy, Bang, Yung-Jue

“…BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF…”
Get full text

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours by van Bussel, Mark T. J., Awada, Ahmad, de Jonge, Maja J. A., Mau-Sørensen, Morten, Nielsen, Dorte, Schöffski, Patrick, Verheul, Henk M. W., Sarholz, Barbara, Berghoff, Karin, El Bawab, Samer, Kuipers, Mirjam, Damstrup, Lars, Diaz-Padilla, Ivan, Schellens, Jan H. M.

“…Background This open-label, phase 1 trial (NCT02316197) aimed to determine the maximum-tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of…”
Get full text

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors by ESKENS, Ferry A. L. M, RAMOS, Francisco J, TABERNERO, Josep, BURGER, Herman, O'BRIEN, James P, PIERA, Adelaida, DE JONGE, Maja J. A, MIZUI, Yoshiharu, WIEMER, Erik A. C, CARRERAS, Maria Josepa, BASELGA, José

“…To assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of E7107 administered as 5-minute bolus infusions on days 1, 8,…”
Get full text

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia by Kreitman, Robert J., Moreau, Philippe, Ravandi, Farhad, Hutchings, Martin, Gazzah, Anas, Michallet, Anne-Sophie, Wainberg, Zev A., Stein, Alexander, Dietrich, Sascha, de Jonge, Maja J. A., Willenbacher, Wolfgang, De Grève, Jacques, Arons, Evgeny, Ilankumaran, Palanichamy, Burgess, Paul, Gasal, Eduard, Subbiah, Vivek

“…•Dabrafenib + trametinib showed durable responses with a manageable safety profile in patients with relapsed/refractory BRAF V600E–mutant HCL.•This combination…”
Get full text

Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial by Virtakoivu, Reetta, Rannikko, Jenna H, Viitala, Miro, Vaura, Felix, Takeda, Akira, Lönnberg, Tapio, Koivunen, Jussi, Jaakkola, Panu, Pasanen, Annika, Shetty, Shishir, de Jonge, Maja J A, Robbrecht, Debbie, Ma, Yuk Ting, Skyttä, Tanja, Minchom, Anna, Jalkanen, Sirpa, Karvonen, Matti K, Mandelin, Jami, Bono, Petri, Hollmén, Maija

“…Macrophages are critical in driving an immunosuppressive tumor microenvironment that counteracts the efficacy of T-cell-targeting therapies. Thus, agents able…”
Get full text

Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study by LoRusso, Patricia, Ratain, Mark J., Doi, Toshihiko, Rasco, Drew W., de Jonge, Maja J. A., Moreno, Victor, Carneiro, Benedito A., Devriese, Lot A., Petrich, Adam, Modi, Dimple, Morgan-Lappe, Susan, Nuthalapati, Silpa, Motwani, Monica, Dunbar, Martin, Glasgow, Jaimee, Medeiros, Bruno C., Calvo, Emiliano

“…Eftozanermin alfa (eftoza), a second-generation tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist, induces apoptosis in tumor…”
Get full text

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation by Lolkema, Martijn P, Bohets, Hilde H, Arkenau, Hendrik-Tobias, Lampo, Ann, Barale, Erio, de Jonge, Maja J A, van Doorn, Leni, Hellemans, Peter, de Bono, Johann S, Eskens, Ferry A L M

“…The receptor tyrosine kinase c-Met plays an important role in tumorigenesis and is a novel target for anticancer treatment. This phase I, first-in-human trial,…”
Get full text

The development of brain metastases in patients with different therapeutic strategies for metastatic renal cell cancer by Derks, Sophie H A E, van der Meer, Edgar L, Joosse, Arjen, de Jonge, Maja J A, Slagter, Cleo, Schouten, Joost W, Hoop, Esther Oomen-de, Smits, Marion, van den Bent, Martin J, Jongen, Joost L M, van der Veldt, Astrid A M

“…A diagnosis of brain metastasis (BM) significantly affects quality of life in patients with metastatic renal cell cancer (mRCC). Although systemic treatments…”
Get full text

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer by Hurley, Rachel M., Wahner Hendrickson, Andrea E., Visscher, Daniel W., Ansell, Peter, Harrell, Maria I., Wagner, Jill M., Negron, Vivian, Goergen, Krista M., Maurer, Matthew J., Oberg, Ann L., Meng, X. Wei, Flatten, Karen S., De Jonge, Maja J.A., Van Herpen, Carla D., Gietema, Jourik A., Koornstra, Rutger H.T., Jager, Agnes, den Hollander, Martha W., Dudley, Matthew, Shepherd, Stacie P., Swisher, Elizabeth M., Kaufmann, Scott H.

“…Poly(ADP-ribose) polymerase (PARP) inhibitors have shown substantial activity in homologous recombination- (HR-) deficient ovarian cancer and are undergoing…”
Get full text

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors by ESKENS, Ferry A. L. M, DE JONGE, Maja J. A, VERWEIJ, Jaap, BHARGAVA, Pankaj, ISOE, Toshiyuki, COTREAU, Monette M, ESTEVES, Brooke, HAYASHI, Kunihiko, BURGER, Herman, THOMEER, Maarten, VAN DOORN, Leni

“…To assess the maximum tolerated dose (MTD)/dose-limiting toxicities (DLT), safety, pharmacokinetics, and pharmacodynamics of tivozanib, a potent and selective…”
Get full text

Core values of patients with advanced cancer considering participation in an early-phase clinical trial: a qualitative study by van Gurp, Jelle L. P., van Lent, Liza G. G., Stoel, Nicole, van der Rijt, Carin C. D., de Jonge, Maja J. A., Pulleman, Saskia M., van Weert, Julia C. M., Hasselaar, Jeroen

“…Objective This article identifies the core values that play a role in patients’ decision-making process about participation in early-phase clinical cancer…”
Get full text

Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study by Posadas, Edwin M, Chi, Kim N, de Wit, Ronald, de Jonge, Maja J A, Attard, Gerhardt, Friedlander, Terence W, Yu, Margaret K, Hellemans, Peter, Chien, Caly, Abrams, Charlene, Jiao, Juhui J, Saad, Fred

“…Apalutamide is a next-generation androgen receptor (AR) inhibitor approved for patients with nonmetastatic castration-resistant prostate cancer (CRPC) and…”
Get full text

Patient values in patient-provider communication about participation in early phase clinical cancer trials: a qualitative analysis before and after implementation of an online value clarification tool intervention by van Lent, Liza G G, van der Ham, Mirte, de Jonge, Maja J A, Gort, Eelke H, van Mil, Marjolein, Hasselaar, Jeroen, van der Rijt, Carin C D, van Gurp, Jelle, van Weert, Julia C M

“…Patients with advanced cancer who no longer have standard treatment options available may decide to participate in early phase clinical trials (i.e…”
Get full text

Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol by Geurts, Birgit S, Zeverijn, Laurien J, Leek, Lindsay V M, van Berge Henegouwen, Jade M, Hoes, Louisa R, van der Wijngaart, Hanneke, van der Noort, Vincent, van de Haar, Joris, van Ommen-Nijhof, Annemiek, Kok, Marleen, Roepman, Paul, Jansen, Anne M L, de Leng, Wendy W J, de Jonge, Maja J A, Hoeben, Ann, van Herpen, Carla M L, Westgeest, Hans M, Wessels, Lodewyk F A, Verheul, Henk M W, Gelderblom, Hans, Voest, Emile E

“…To evaluate efficacy of pembrolizumab across multiple cancer types harboring different levels of Whole-Genome Sequencing (WGS)-based tumor mutational load…”
Get full text

Comprehensive characterization of circulating tumor cells and cell‐free DNA in patients with metastatic melanoma by Bos, Manouk K., Kraan, Jaco, Starmans, Martijn P. A., Helmijr, Jean C. A., Verschoor, Noortje, De Jonge, Maja J. A., Joosse, Arjen, Veldt, Astrid A. M., Boekhorst, Peter A. W., Martens, John W. M., Sleijfer, Stefan, Wilting, Saskia M.

“…Advances in therapeutic approaches for melanoma urge the need for biomarkers that can identify patients at risk for recurrence and to guide treatment. The…”
Get full text

A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors by Puglisi, Martina, Molife, L Rhoda, de Jonge, Maja Ja, Khan, Khurum H, Doorn, Leni van, Forster, Martin D, Blanco, Montserrat, Gutierrez, Martin, Franklin, Catherine, Busman, Todd, Yang, Jianning, Eskens, Ferry Alm

“…This Phase I study investigated safety of navitoclax and docetaxel in patients (n = 41) with advanced solid tumors. Two navitoclax plus docetaxel dosing…”
Get full text

Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors by STEEGHS, Neeltje, ESKENS, Ferry A. L. M, LAFFRANCHI, Bernard, DE JONGE, Maja J. A, GELDERBLOM, Hans, VERWEIJ, Jaap, NORTIER, Johan W. R, OUWERKERK, Jan, VAN NOORT, Conny, MARIANI, Mariangela, SPINELLI, Riccardo, CARPINELLI, Patrizia

“…Danusertib (PHA-739358) is a small-molecule pan-aurora kinase inhibitor. This phase I dose escalation study was conducted to evaluate safety and tolerability…”
Get full text

Identifying patient values impacting the decision whether to participate in early phase clinical cancer trials: A systematic review by van Lent, Liza G.G., Jabbarian, Lea J., van Gurp, Jelle, Hasselaar, Jeroen, Lolkema, Martijn P., van Weert, Julia C.M., van der Rijt, Carin C.D., de Jonge, Maja J.A.

“…•A systematic overview of values relevant to advanced cancer patients is presented.•Patients who seek trial participation report e.g. hope, trust and/or…”
Get full text

Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation by de Jonge, Maja J.A, Slingerland, Marije, Loos, Walter J, Wiemer, Erik A.C, Burger, Herman, Mathijssen, Ron H.J, Kroep, Judith R, den Hollander, Margret A.G, van der Biessen, Diane, Lam, Mei-Ho, Verweij, Jaap, Gelderblom, Hans

“…Abstract Purpose To evaluate the safety and tolerability of LiPlaCis, a liposomal formulated platinum compound, in patients with solid tumours and to determine…”
Get full text

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies by de Jonge, Maja J. A., Steeghs, Neeltje, Lolkema, Martijn P., Hotte, Sebastien J., Hirte, Hal W., van der Biessen, Diane A. J., Abdul Razak, Albiruni R., De Vos, Filip Y. F. L., Verheijen, Remy B., Schnell, David, Pronk, Linda C., Jansen, Monique, Siu, Lillian L.

“…Background Overexpression/activation of focal adhesion kinase (FAK) in human malignancies has led to its evaluation as a therapeutic target. We report the…”
Get full text